James C. Lin
Lawyers
Filters
Carsome Group $290 million Series E funding round
We are advising Carsome on its Series E funding round
BeiGene RMB22.2 billion Shanghai IPO
The offering, equivalent to $3.5 billion, is the largest biotech IPO to date in 2021
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
FiscalNote business combination with Duddell Street Acquisition Corp.
We are advising Duddell Street, a SPAC, on the transaction
Sea $6.9 billion concurrent convertible notes and equity offerings
We advised the joint book-running managers on the concurrent offerings of convertible senior notes and ADSs
Baidu $1 billion sustainability notes offering
The investment-grade offering included notes due 2027 and 2031
Baidu $1 billion notes offering
We advised the underwriters on the investment-grade debt offering
SOPHiA GENETICS $234 million IPO and $20 million private placement
We advised SOPHiA GENETICS on its IPO, Nasdaq listing and concurrent private placement
Black Spade Acquisition $150 million IPO
We advised Black Spade, a SPAC, on its IPO and NYSE listing
Gobi Acquisition $250 million IPO
We advised the joint book-running managers on the SPAC IPO and Nasdaq listing